Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Inclusion Criteria:

• Any patients with suspected (clinical) or definitive (tissue) diagnosis of StageIII-IV melanoma starting or continuing adjuvant Pembrolizumab without activeevidence of disease (NED).

• Must be treatment naïve or have had treatment no less than 6 months prior toenrollment

• 18 years or older

• Must be able to take pills

• ECOG performance status of 0-3

• Ability to understand and willingness to sign a written informed consent

• Members of all racial and ethnic groups are eligible for this study

Exclusion Criteria:

• History of hypersensitivity reactions attributed to beta-glucan

• Patients receiving continuous or other ongoing immunosuppressive therapy

• Uncontrolled intercurrent illness including, but not limited to, autoimmunediseases, ongoing or active infection, symptomatic congestive heart failure,unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/socialsituations that would limit compliance with study requirements

• Any patients who have serious autoimmune toxicity during the study period, or thosewho have disease recurrence during the 6-week study period should be excluded andanalyzed separately

• Patients with mucosal melanoma

• Patients with concurrent malignancy or recent history thereof